Ozempic is generally safe when prescribed and monitored by a doctor, but it is not FDA-approved for weight loss. It’s approved to treat type 2 diabetes and reduce cardiovascular risk in diabetic patients. When doctors prescribe it specifically for weight loss, that’s considered off-label use. The same active ingredient, semaglutide, is approved for weight loss under a different brand name (Wegovy) at a higher dose. This distinction matters because the safety data, dosing, and insurance coverage differ between the two.
That said, millions of people are using Ozempic off-label for weight loss, and the drug’s safety profile is well-studied across multiple clinical trials lasting up to two years. Here’s what the evidence shows about both the benefits and the risks.
How Effective It Is for Weight Loss
In a 68-week clinical trial, participants taking semaglutide alongside lifestyle changes (diet and exercise) lost an average of 14.9% of their body weight, compared to just 2.4% in the placebo group. For someone weighing 220 pounds, that translates to roughly 33 pounds over about 16 months. These results are significant, but they require ongoing use. Most people regain weight after stopping the medication.
Common Side Effects
The most frequent side effects are gastrointestinal: nausea, vomiting, diarrhea, abdominal pain, and constipation. These affect a meaningful number of users. In clinical trials, about 30 to 34% of people experienced GI symptoms, depending on the dose. The side effects tend to be worst during the first few weeks and often improve as your body adjusts.
To reduce these effects, doctors start patients on a low dose and increase it gradually over several weeks. The starting dose is much lower than the treatment dose, and increases happen at four-week intervals. Even so, roughly 3 to 4% of trial participants stopped the drug because of GI problems.
Practical tips that help: eating smaller meals, avoiding fatty or greasy foods, and eating slowly. If nausea persists beyond the first month or two at a given dose, that’s worth discussing with your prescriber before moving to a higher dose.
The Black Box Warning: Thyroid Tumors
Ozempic carries the FDA’s most serious warning label. In animal studies, semaglutide caused thyroid C-cell tumors at doses similar to what humans take. Whether this translates to a real risk in people remains unknown. No definitive link to thyroid cancer has been established in human trials, but the studies haven’t run long enough to rule it out with certainty.
Because of this uncertainty, Ozempic is completely off-limits if you have a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. If you notice a lump in your neck, difficulty swallowing, or persistent hoarseness while taking the drug, those symptoms need prompt evaluation.
Other Serious Risks
Beyond the thyroid warning, several less common but serious risks have surfaced in clinical trials:
- Gallstones. About 1.5% of Ozempic users developed gallstones in clinical trials, compared to 0.4% on placebo. Rapid weight loss from any cause increases gallstone risk, so this isn’t unique to semaglutide, but the rate is notably higher.
- Pancreatitis. Inflammation of the pancreas has been reported. In one two-year study, the rate was actually similar between Ozempic and placebo groups (8 cases vs. 10), so the connection remains unclear. Severe, persistent abdominal pain that radiates to your back is the hallmark symptom.
- Diabetic retinopathy complications. In a two-year trial, 3% of Ozempic users experienced eye complications related to diabetes, compared to 1.8% on placebo. This is primarily a concern for people with existing diabetes and eye disease, not for those using it purely for weight loss.
There’s also been media attention around gastroparesis, a condition where the stomach empties abnormally slowly. Ozempic does slow stomach emptying as part of how it works, which is why people feel full longer. However, current research has not established a clear link between the drug and true gastroparesis. The nausea, vomiting, and bloating that some users experience overlap with gastroparesis symptoms, which has created confusion. The medical literature on this is still inconclusive.
Muscle Loss Is a Real Concern
One underappreciated risk of Ozempic is how much of the weight you lose comes from muscle rather than fat. Studies suggest that 25 to 39% of the total weight lost on semaglutide is lean mass (muscle and other non-fat tissue) over 36 to 72 weeks. That’s a higher proportion than what you’d typically see with diet alone, where muscle loss accounts for 10 to 30% of weight lost.
Losing muscle matters because it affects your metabolism, strength, balance, and bone health, especially as you age. Resistance training and adequate protein intake can help preserve muscle during treatment. Some clinicians now monitor muscle strength and nutritional status alongside standard lab work during follow-up visits, which typically happen monthly at first and then every three months once the dose is stable.
Who Should Not Take It
Ozempic is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It’s also off-limits if you’ve had an allergic reaction to semaglutide or any of its ingredients.
Beyond the formal contraindications, people with a history of pancreatitis, severe GI disorders, or significant kidney problems need careful evaluation before starting. Pregnant or breastfeeding individuals should not use it. And because Ozempic is approved for type 2 diabetes, using it off-label for weight loss means your doctor is making a clinical judgment that the benefits outweigh the risks for your specific situation.
Off-Label Use vs. Wegovy
If your primary goal is weight loss and you don’t have type 2 diabetes, Wegovy is the FDA-approved option. It contains the same drug at a higher maximum dose (2.4 mg weekly vs. Ozempic’s 2 mg maximum) and was specifically studied in weight-loss trials. The safety profiles overlap significantly, but Wegovy’s clinical trials were designed around weight management outcomes, giving doctors more relevant data to work with.
Many people end up on Ozempic for weight loss because of Wegovy’s ongoing supply shortages or insurance coverage differences. This is a practical reality, but it’s worth understanding that your doctor is working with a drug that wasn’t tested and approved for this specific purpose, even though the active ingredient is identical.
What Safety Monitoring Looks Like
If you’re prescribed Ozempic, expect regular check-ins. Most doctors schedule a follow-up about one month after starting, then shift to every three months once you’re on a stable dose. These visits typically cover how you’re tolerating the medication, whether GI symptoms are manageable, your weight trajectory, blood sugar levels, kidney function, and nutritional status. Some clinicians also track bone health and muscle strength over time, particularly in older patients or those losing weight rapidly.
The longest clinical trials for Ozempic have followed patients for about 41 months, roughly three and a half years. That’s a reasonable window, but it means true long-term effects over five or ten years are not yet fully understood. For a drug that many people plan to take indefinitely, this is an important gap in the evidence.